An observational study in Kidney Function Decline, Chronic Kidney Disease and Kidney Failure, sponsored by Huashan Hospital. Completed at 1 site in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Huashan Hospital · Observational
This completed observational cohort study evaluates a comprehensive set of clinical and molecular markers of kidney function in two established cohorts of Chinese adults aged 60 years or older. The study assesses markers reflecting glomerular filtration, kidney tubular transport, and kidney endocrine function and evaluates their associations with kidney failure, cardiovascular and cerebrovascular events, and all-cause mortality. It also compares approaches to estimating glomerular filtration rate and develops and internally validates an early-warning model for kidney function decline. Existing baseline and follow-up data and stored serum and urine specimens are used. No intervention or additional study-specific clinical procedure is administered.
The study includes 5,588 participants, comprising 1,788 participants from the Rugao Longevity and Ageing Study and 3,800 participants from the Shanghai Older-Adult Cohort. The study uses existing demographic, lifestyle, clinical, and laboratory data, longitudinal follow-up information, and measurements obtained from stored serum and urine specimens. No intervention is assigned, and no additional study-specific examination or biospecimen collection is performed.
Markers reflecting glomerular filtration, kidney tubular transport, and kidney endocrine function are evaluated in relation to incident kidney failure, cardiovascular and cerebrovascular events, and all-cause mortality. Approaches to estimating glomerular filtration rate and combinations of kidney function-related biomarkers are compared for prognostic assessment. Multivariable linear, logistic, and Cox proportional hazards regression models are used, as appropriate, to evaluate associations while accounting for potential confounding factors.
For prediction modeling, the analytic sample is divided in a 7:3 ratio into model-development and internal-validation sets. Statistical learning and machine-learning methods, including random forests, decision trees, support vector machines, and neural-network approaches, are evaluated. Cross-validation is used during model development and model selection. The study also supports the development of a secure, access-controlled data-sharing and analytics platform.
The study population comprises adults aged 60 years or older selected from two established Chinese cohorts. The Rugao Longevity and Ageing Study primarily includes community-dwelling older adults, whereas the Shanghai Older-Adult Cohort includes older adults with comorbid conditions. Eligible participants had a baseline estimated glomerular filtration rate greater than 60 mL/min/1.73 m² and the clinical, follow-up, and biospecimen data required for the relevant analyses.
Exclusion Criteria:
This cohort comprises eligible older adults from the established Rugao Longevity and Ageing Study. Participants contribute existing baseline and follow-up data and, when available, stored serum and urine specimens. No intervention is assigned. Clinical and molecular markers of kidney function are evaluated in relation to subsequent kidney failure, cardiovascular and cerebrovascular events, and all-cause mortality.
This cohort comprises eligible older adults with comorbid conditions from the established Shanghai Older-Adult Cohort. Participants contribute existing baseline and follow-up data and, when available, stored serum and urine specimens. No intervention is assigned. Clinical and molecular markers of kidney function are evaluated in relation to subsequent kidney failure, cardiovascular and cerebrovascular events, and all-cause mortality.
Incident End-Stage Kidney Disease
First occurrence of end-stage kidney disease documented in cohort follow-up or clinical records.
Time frame: From cohort baseline through the end of available follow-up, up to 10 years
Incident Cardiovascular or Cerebrovascular Event
First occurrence of a clinically documented cardiovascular or cerebrovascular event, including coronary heart disease, myocardial infarction, heart failure, or stroke, ascertained from cohort follow-up and medical records.
Time frame: From cohort baseline through the end of available follow-up, up to 10 years
All-Cause Mortality
Death from any cause, ascertained from survival follow-up and death records.
Time frame: From cohort baseline through the end of available follow-up, up to 10 years
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Huashan Hospital